SHAREHOLDER ALERT: Weiss Law Investigates Checkmate Pharmaceuticals, Inc.

NEW YORK , April 19, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate Pharmaceuticals, Inc. ("Checkmate" or the "Company") (NASDAQ: CMPI), in connection with the proposed acquisition of the Company by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $10.50 in cash for each share of Checkmate common stock owned. The transaction is valued at $250 million.